Germany's Merck KGaA is buying U.K. gene-silencing biotech for $1.3 billion
- U.K.: 39 events in the last 90 days
- Previous: earlier the same day · Microsoft pulled out of a U.K. data center deal, clouding Nscale's IPO hopes
What happened
The all-cash deal adds divesiran, an experimental rare-disease drug ready for late-stage trials, to Merck's pipeline
Summary assembled by rule from the sources below